title: Human papillomavirus (HPV) and HPV 16-variant distribution in vulvar squamous cell carcinoma in Sweden.
abstract: OBJECTIVE
  To investigate the human papillomavirus (HPV) and HPV type 16-variant distribution in a series of vulvar squamous cell carcinomas (VSCC) and to evaluate the impact of HPV and HPV 16-variant on prognosis.
  
  
  METHODS
  A series of 133 patients who had a diagnosis of VSCC (1983-2008) was selected for the study. Detection of 11 high-risk HPV types (16, 18, 31, 33, 39, 45, 51, 52, 56, 58, and 59) and 2 low-risk HPV types (6 and 11) was performed with real-time polymerase chain reaction. Samples positive for HPV 16 were further analyzed for variant determination of 7 positions in the E6 gene with polymerase chain reaction and pyrosequencing.
  
  
  RESULTS
  Forty (30.8%) of 130 tumors were found to be HPV positive. Human papillomavirus type 16 was found in 31 cases, HPV 18 was found in 2 cases, HPV 33 was found in 5 cases, and HPV 56 and HPV 59 were found in one case each. All but one tumor harboring HPV 16 were of European linage, and the 3 most common variants were E-p (n = 13), E-G350 (n = 7), and E-G131 (n = 5). HPV positivity was associated with the basaloid tumor type and occurred in significantly younger patients. Overall and recurrence-free survival rates were better in HPV-positive cases, but after correction for age and tumor size, HPV status was no longer an independent and significant prognostic factor. The survival rates of the various HPV 16 variants were not significantly different, but there was a trend of worse outcome for the E-G131-variant group.
  
  
  CONCLUSIONS
  Human papillomavirus positivity of 30.8% is similar to other reports on VSCC. To our knowledge, this first variant determination of HPV 16 in vulvar carcinoma in a Swedish cohort indicated that the variant E-G131 may have an increased oncogenic potential in patients with VSCC.
authors.affiliation: Department of Laboratory Medicine, Örebro University Hospital, Örebro University, Örebro, Sweden. gabriella.lillsunde-larsson@orebroll.se
authors.forename: Gabriella Lillsunde
authors.initials: GL
authors.lastname: Larsson
authors.forename: Gisela
authors.initials: G
authors.lastname: Helenius
authors.forename: Sören
authors.initials: S
authors.lastname: Andersson
authors.forename: Fredrik
authors.initials: F
authors.lastname: Elgh
authors.forename: Bengt
authors.initials: B
authors.lastname: Sorbe
authors.forename: Mats G
authors.initials: MG
authors.lastname: Karlsson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000401:mortality / Q000821:virology*; D004279:DNA, Viral / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D052162:Human papillomavirus 16 / Q000235:genetics*; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000235:genetics / Q000401:mortality / Q000821:virology*; D009367:Neoplasm Staging; D027383:Papillomaviridae / Q000145:classification* / Q000235:genetics; D030361:Papillomavirus Infections / Q000235:genetics / Q000473:pathology / Q000821:virology*; D011379:Prognosis; D060888:Real-Time Polymerase Chain Reaction; D015996:Survival Rate; D013548:Sweden; D014846:Vulvar Neoplasms / Q000235:genetics / Q000401:mortality / Q000821:virology*
chemical_list: D004279:DNA, Viral